IL17A and autoimmune disease: Given that current therapeutic investigations revealed that MIF and IL-17 deficiency through genetic deletion or Abs neutralization results in protection or release from several animal models of inflammatory and autoimmune disease [9, 10, 24–27, 36], clinical application still needs further in-depth research.